Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
31-45 of 4506 results
Janssen scraps hepatitis C development program
By PBR Staff Writer
Janssen Sciences Ireland UC has scrapped its ongoing hepatitis C development program citing the growing number of therapies available for treating the disease effectively.
Drug Research > Drug Discovery & Development > News
Boehringer Ingelheim, Gubra to develop next generation obesity treatments
Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity.
Drug Research > Drug Discovery & Development > News
European Investment Bank grants €75m funding for Evotec
Evotec and the European Investment Bank (EIB) announced that the EIB has granted Evotec an unsecured loan facility of up to €75m to support Evotec's Innovate strategy.
Drug Research > Drug Discovery & Development > News
GSK exercises option on phase I/II NY-ESO T-cell therapy
GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794).
Drug Research > Drug Discovery & Development > News
Jazz Pharmaceuticals, ImmunoGen to collaborate on hematology-related ADC products
By PBR Staff Writer
Ireland-based Jazz Pharmaceuticals has partnered with ImmunoGen to develop and commercialize the US biotechnology company’s two early-stage, hematology-related antibody-drug conjugate (ADC) products.
Drug Research > Drug Discovery & Development > News
CSL Behring to buy US biotechnology firm Calimmune
By PBR Staff Writer
CSL Behring, the US subsidiary of Australia-based CSL has agreed to acquire Calimmune, an American biotechnology company focused on developing ex vivo hematopoietic stem cell (HSC) gene therapy.
Drug Research > Drug Discovery & Development > News
Regenxbio to buy US firm Dimension Therapeutics
By PBR Staff Writer
Gene therapy firm Regenxbio has signed an agreement to acquire US-based firm Dimension Therapeutics.
Drug Research > Drug Discovery & Development > News
Ligand to receive $2m from WuXi for licensing clinical-stage anti-PD-1 antibody
Ligand Pharmaceuticals will get a payment of $2m from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and other selected territories.
Drug Research > Drug Discovery & Development > News
Samsung Bioepis, Takeda to co-develop multiple novel biologic therapies
Samsung Bioepis has signed collaboration agreement with Takeda Pharmaceutical to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas.
Drug Research > Drug Discovery & Development > News
Atreca raises $35m to advance novel cancer immunotherapies
Atreca, a privately held biotechnology company developing novel therapeutics drawn from human immune responses, has closed its Series B round of financing with an investment totaling $35m.
Drug Research > Drug Discovery & Development > News
GSK to evaluate Insilico’s AI technology to enhance drug discovery process.
By PBR Staff Writer
GlaxoSmithKline and Insilico Medicine are partnering to assess how the latter’s artificial intelligence (AI) technology can help in the drug discovery process.
Drug Research > Drug Discovery & Development > News
Evotec completes Aptuit acquisition
German company Evotec has completed the acquisition of US-based Aptuit.
Drug Research > Drug Discovery & Development > News
Vicarius Pharma secures $21.8m financing
Vicarius Pharma has secured a CHF21m ($21.8m) investment through a Series A preferred stock financing from private investors.
Drug Research > Drug Discovery & Development > News
Oxford BioMedica announces collaboration for gene and cell therapy manufacturing
A new consortium, led by Oxford BioMedica, will take part in a two-year, £2m project focused on gene and cell therapy manufacturing.
Drug Research > Drug Discovery & Development > News
Apellis Pharmaceuticals raises $60m in new funding round
Apellis Pharmaceuticals has completed a $60m Series E preferred stock financing led by Sectoral Asset Management.
Drug Research > Drug Discovery & Development > News
31-45 of 4506 results